This HTML5 document contains 60 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00138/identifier/pharmgkb/
n16http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00138/identifier/kegg-compound/
n14http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB00138/identifier/kegg-drug/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00138/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/drugbank/medicinal-product/
n4http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n20http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/
n3http://linked.opendata.cz/ontology/drugbank/
n13http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/drugbank/drug/DB00138/identifier/chebi/

Statements

Subject Item
n2:DB00138
rdf:type
n3:Drug
n3:description
A covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine. [PubChem]
n3:group
approved nutraceutical
n3:indication
It has been claimed that L-cysteine has anti-inflammatory properties, that it can protect against various toxins, and that it might be helpful in osteoarthritis and rheumatoid arthritis. More research will have to be done before L-cysteine can be indicated for any of these conditions. Research to date has mostly been in animal models.
owl:sameAs
n11:DB00138 n14:DB00138
dcterms:title
L-Cystine
adms:identifier
n7:16283 n8:C00491 n9:D03636 n12:DB00138 n15:PA449176
n3:mechanismOfAction
Certain conditions, e.g. an acetaminophen overdose, deplete hepatic glutathione and subject the tissues to oxidative stress resulting in loss of cellular integrity. L-Cystine serves as a major precursor for synthesis of glutathione.
n3:packager
n16:271B4A04-363D-11E5-9242-09173F13E4C5 n16:271B4A03-363D-11E5-9242-09173F13E4C5
n3:synonym
L-alpha-Diamino-beta-dithiolactic acid L-Dicysteine (R,R)-3,3'-dithiobis(2-aminopropanoic acid) β,β'-dithiodialanine
n3:toxicity
With typical doses of 1 to 1.5 grams daily, the most commonly reported side effects have been gastrointestinal, such as nausea. There are rare reports of cystine renal stone formation, Single injections of L-cysteine (0.6-1.5 g/kg) into 4-day-old pups resulted in massive damage to cortical neurons, permanent retinal dystrophy, atrophy of the brain and hyperactivity.
n3:synthesisReference
Peter Stehle, Peter Furst, Werner Fekl, "N,N'-bis-L-amino acid-L-cystine-peptide containing amino acid preparations for oral parenteral nutrition." U.S. Patent US4968696, issued February, 1964.
n4:hasConcept
n5:M0005555
foaf:page
n20:lcy_0088.shtml
n3:IUPAC-Name
n13:271B4A0C-363D-11E5-9242-09173F13E4C5
n3:InChI
n13:271B4A12-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n13:271B4A11-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n13:271B4A0E-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n13:271B4A0F-363D-11E5-9242-09173F13E4C5
n3:SMILES
n13:271B4A10-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n13:271B4A0A-363D-11E5-9242-09173F13E4C5 n13:271B4A22-363D-11E5-9242-09173F13E4C5
n3:logP
n13:271B4A0B-363D-11E5-9242-09173F13E4C5 n13:271B4A08-363D-11E5-9242-09173F13E4C5 n13:271B4A24-363D-11E5-9242-09173F13E4C5
n3:logS
n13:271B4A09-363D-11E5-9242-09173F13E4C5
n3:pKa
n13:271B4A25-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n13:271B4A18-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n13:271B4A19-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n13:271B4A13-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n13:271B4A14-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n13:271B4A16-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n13:271B4A15-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n13:271B4A17-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
56-89-3
n3:category
n3:containedIn
n17:271B4A07-363D-11E5-9242-09173F13E4C5 n17:271B4A05-363D-11E5-9242-09173F13E4C5 n17:271B4A06-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n13:271B4A1E-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n13:271B4A20-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n13:271B4A21-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n13:271B4A23-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n13:271B4A1D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n13:271B4A1C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n13:271B4A1F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n13:271B4A0D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n13:271B4A1A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n13:271B4A1B-363D-11E5-9242-09173F13E4C5